$52.10
▼ -1.1% Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
TGTX: Lowering target price to $59.00
TGTX: Lowering target price to $60.00
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations
Overview
52-week range
$25
$45
100% of range
Avg surprise (last 3)
-52.1%
Avg reaction (last 2)
+1.5%
50% positive
Latest IV / EM
66%
EM ±15.2% · $55 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $0.17 | $0.23 | -26.1% | +466.7% | +16.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $2.43 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $0.17 | $0.32 | -46.9% | — | — | earnings |
| Mon May 5, 2025 | Mar/2025 | $0.03 | $0.18 | -83.3% | — | -13.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.04 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.34 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 3, 2026 | Jun/2026 | OTHER | $0.41 | $0.17 | +141.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $35M | — | $29M | $35M | $9M | — | $12M | $9M |
| Net income | $20M | — | $391M | $28M | $5M | — | $4M | $7M |
| EPS (diluted) | $0.12 | — | $2.43 | $0.17 | $0.03 | — | $0.02 | $0.04 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $442M | $79M | $74M | $129M | $132M | $180M | $196M | $83M |
| Inventory | $129M | $126M | $147M | $155M | $158M | $110M | $85M | $81M |
| Total current assets | $1.09B | $631M | $600M | $664M | $645M | $566M | $574M | $389M |
| Total assets | $1.53B | $1.06B | $1.03B | $703M | $657M | $578M | $586M | $401M |
| Long-term debt | $745M | $246M | $245M | $245M | $245M | $244M | $244M | $103M |
| Total liabilities | $946M | $415M | $418M | $426M | $419M | $355M | $394M | $224M |
| Total equity | $583M | $648M | $607M | $276M | $237M | $222M | $192M | $178M |